Issued: 8 March 2022, London UK GlaxoSmithKline plc Annual Report 2021 on Form 20-F In accordance with Section 203.01 of the New York Stock Exchange Listed Company Manual, GlaxoSmithKline plc ("GSK") announces that on 8 March 2022 it filed with the Securities and Exchange Commission an Annual...
Annual Report 2022 ESEF (ZIP - 13.5MB) 20-F 2022 (PDF - 4.1MB) Download all Corporate reporting 2022 02 March 2022 Corporate reporting 2021 Annual Report 2021 (PDF - 4.8MB) ESG Performance Summary 2021 20-F 2021 (PDF - 3.3MB) Xbrl Interactive Data File 2021 Download all ...
GlaxoSmithKline Pharmaceuticals Limited | Annual Report 2021-22 GSK plc at a glance Our purpose We unite science, technology and talent to get ahead of disease together For health impact + shareholder returns + thriving people About our new logo The new logo reflects our new purpose and growth ...
Antimicrobial Resistance Benchmark 84% 86% Led the bi-annual benchmark since its inception in 2018; Current ranking updated November 2021 CDP Climate change A- A- Updated annually, current score updated February 2024 CDP Water security A- B Updated annually, current score updated February 2024 CD...
Such factors include, but are not limited to, those described in the Company's Annual Report on Form 20-F for 2021, GSK’s Q2 Results for 2022 and any impacts of the COVID-19 pandemic. [1] US Centers for Disease Control and Prevention, Fact facts – pneumococcal disease. Available ...
Annual report 2021 [https://www.gsk.com/media/7462/annual-report-2021.pdf]. 9 GSK globally The company offers a portfolio of vaccines, specialty medicines and general medicines across 4 major therapeutic areas: infectious diseases, HIV, oncology and respiratory/ immunology. 1.2 Product portfolio ...
Such factors include, but are not limited to, those described in the Company's Annual Report on Form 20-F for 2021, GSK’s Q2 Results for 2022 and any impacts of the COVID-19 pandemic. [1] US Centers for Disease Control and Prevention, Fact facts – pneumococcal disease. Available ...
Lastly, this slide summarizes key data we expect to report over the next 18 months. As you can see, we anticipate a large number of pivotal data readout from 2022 as well as some important data points in the second half of 2021. Among our specialty products, I have already spoken about...
including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D "Risk factors" in GSK's Annual Report on Form 20-F for 2023...
This statistic was assembled from several editions of the GSK Annual Report. * Reflects the spin-off of the Consumer Healthcare business. Open this statistic in... Spanish Citation formats Citation formats View options Other statistics on the topicPharmaceutical industry in the UK ...